Type 2 Diabetes

A recent study showed that very low-energy diets and formula meal replacements were the most effective weight-loss diets among patients with type 2 diabetes. It was the top story in endocrinology last week.

For patients with chronic kidney disease, dapagliflozin slowed long-term decreases in the eGFR.

When I transfer what we learned as educators and clinicians from blood glucose monitoring to CGM, the lessons are similar. With CGM, people using insulin, whether with type 1 or type 2 diabetes, derive great benefit. We certainly use CGM for people with type 2 diabetes prescribed multiple daily injections. In the MOBILE study, we showed how much CGM could help people using basal insulin, though I believe, with more training, we could have done even better.

Continuous glucose monitoring, first approved by the FDA for professional use in 1999, has become standard of care for people with type 1 diabetes, with benefits for improved glucose management, health outcomes and quality of life.

Adults in South Korea with diabetes had a higher risk for cardiovascular disease, coronary heart disease and peripheral arterial disease if they had low appendicular skeletal muscle mass and low grip strength, according to study data.

Diabetic peripheral neuropathy is associated with a decline in cognition for people with type 2 diabetes, according to study findings published in the Journal of Diabetes and its Complications.

Weight-loss programs that include very low-energy diets and formula meal replacements are the most effective for weight loss in type 2 diabetes, according to a systematic review published in Diabetologia.

New data showed that hormone therapy during menopause did not increase the risk for CVD or type 2 diabetes among middle-aged postmenopausal women. A report on the findings was the top story in endocrinology last week.

Daily low-dose aspirin use over 7 years did not affect the risk for incident dementia or cognitive decline in U.K. adults with type 2 diabetes, according to new data from the ASCEND trial.

Daily low-dose aspirin use over 7 years did not affect the risk for incident dementia or cognitive decline in U.K. adults with type 2 diabetes, according to new data from the ASCEND trial.